Latest Boehringer Ingelheim Stories
- Less than 1 in 3 patients and caregivers are prepared for how IPF will affect their daily life RIDGEFIELD, Conn., Feb.
LONDON, February 10, 2015 /PRNewswire/ -- Report Details What are the commercial prospects for pharmaceutical [https://www.visiongain.com/Pharma/47/Reports
Spanish-Language Resources Encourage Holding On to the Gift of Health RIDGEFIELD, Conn., Feb. 10, 2015 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc.
Only prescription medication in U.S. to combine the dual mechanisms of action of SGLT2 and DPP-4 inhibitors to improve glycemic control as an adjunct to diet and exercise RIDGEFIELD, Conn.
Redesigned Bi-vetmedica.com Features Mobile-ready Options, Online Research and Catalog of Scientific Publications by Knowledge Leaders ST. JOSEPH, Mo., Feb.
DiabetesSisters has received joint funding from Boehringer-Ingelheim and Eli Lilly in the amount of $50,0000 to support the creation of DiabetesSisters’ first Educational Library.
New choice between mist and dry powder inhalers for tiotropium RIDGEFIELD, Conn., Jan. 21, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
OXFORD, England, January 14, 2015 /PRNewswire/ -- Oxford BioTherapeutics announces today that Boehringer Ingelheim has exercised an option to receive exclusive rights to
HEIDELBERG, Germany, January 5, 2015 /PRNewswire/ -- BioMed X announced today that they have entered into a collaboration agreement with Boehringer Ingelheim to establish
- Growing in low tufty patches.